Arcturus announces regulatory approval to proceed with phase 2 study of arct-810 mrna therapeutic candidate for ornithine transcarbamylase (otc) deficiency

San diego--(business wire)---- $arct #clinicaltrial--arcturus announces regulatory approval to proceed with phase 2 study of arct-810 mrna therapeutic candidate for otc deficiency
ARCT Ratings Summary
ARCT Quant Ranking